Medscape |
FDA Panel Backs Mepolizumab for Severe Eosinophilic Asthma
Medscape A typical characteristic of mild asthma is airway inflammation due to eosinophils, and this inflammation is closely associated with the risk for severe asthma exacerbations. Several products are approved for long-term maintenance treatment of asthma … FDA panel backs approval of GSK asthma drug in adults Asthma Drug Targeting IL-5 Wins Partial Backing From FDA Advisers UPDATE: Glaxo's (GSK) Severe Asthma Drug Mepolizumab Found Effective in … |
View full post on asthma – Google News